United Therapeutics stock price target raised to $580 by UBS on Tyvaso outlook
PositiveFinancial Markets

UBS has raised its price target for United Therapeutics to $580, driven by a positive outlook on the company's Tyvaso product. This adjustment reflects growing confidence in Tyvaso's market potential and United Therapeutics' overall performance, which could lead to increased investor interest and a stronger stock position.
— Curated by the World Pulse Now AI Editorial System